These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37557151)

  • 1. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
    Duraisamy P; Panicker VV; Jose WM
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    medRxiv; 2023 Jan; ():. PubMed ID: 36711758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
    Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
    Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
    Curkovic NB; Bai K; Ye F; Johnson DB
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity - a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital.
    Juan-Carpena G; Martínez-Banaclocha N; Palazón-Cabanes JC; Niveiro-de Jaime M; Betlloch-Mas I; Blanes-Martínez M
    Clin Exp Dermatol; 2024 Aug; 49(9):991-1001. PubMed ID: 38372424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
    Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
    JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
    Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
    Luangnara A; Kiratikanon S; Ketpueak T; Suksombooncharoen T; Charoentum C; Chewaskulyong B; Tovanabutra N; Chiewchanvit S; Nochaiwong S; Chuamanochan M
    Front Immunol; 2022; 13():965550. PubMed ID: 36341419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
    Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
    JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
    Du Y; Wu W; Chen M; Dong Z; Wang F
    JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
    Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
    Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
    Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
    J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit.
    Cho YT; Lin YT; Yang CW; Chu CY
    Sci Rep; 2022 Apr; 12(1):7021. PubMed ID: 35487955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
    Nadelmann ER; Yeh JE; Chen ST
    JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INDIVIDUAL ARTICLE: NECOM 4: Algorithm Integrating Skincare for the Management of Immunotherapy-Related Cutaneous Adverse Events for Cancer Patients and Survivors.
    Girnita A; Fournier C; Bjerring P; Kauppi S; Andriessen A; Lynde C; Sauder M; Stensvold A
    J Drugs Dermatol; 2024 Aug; 23(8):85411s3-85411s10. PubMed ID: 39093665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
    Cao T; Zhou X; Wu X; Zou Y
    Front Immunol; 2023; 14():1207544. PubMed ID: 37497220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study.
    Wan G; Nguyen N; Leung BW; Rashdan H; Tang K; Roster K; Collier MR; Ugwu-Dike PO; Raval NS; Alexander NA; Jairath R; Phillipps J; Amadife M; Zhang S; Gusev A; Chen ST; Reynolds KL; LeBoeuf NR; Kwatra SG; Semenov YR
    medRxiv; 2023 Aug; ():. PubMed ID: 37693493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
    Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
    J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.